# Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

> **NCT06287398** · PHASE2 · RECRUITING · sponsor: **Australasian Leukaemia and Lymphoma Group** · enrollment: 39 (estimated)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- DLBCL, Nos Genetic Subtypes
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Follicular Large Cell Lymphoma, Relapsed
- Follicular Large Cell Lymphoma

## Interventions

- **DRUG:** Epcoritamab

## Key facts

- **NCT ID:** NCT06287398
- **Lead sponsor:** Australasian Leukaemia and Lymphoma Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2026-11
- **Final completion:** 2031-11
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06287398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06287398, "Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06287398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*